Amiodarone-associated changes in human neutrophils
The American Journal of Cardiology, ISSN: 0002-9149, Vol: 57, Issue: 8, Page: 666-672
1986
- 17Citations
- 2Captures
Metric Options: CountsSelecting the 1-year or 3-year option will change the metrics count to percentiles, illustrating how an article or review compares to other articles or reviews within the selected time period in the same journal. Selecting the 1-year option compares the metrics against other articles/reviews that were also published in the same calendar year. Selecting the 3-year option compares the metrics against other articles/reviews that were also published in the same calendar year plus the two years prior.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Example: if you select the 1-year option for an article published in 2019 and a metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019. If you select the 3-year option for the same article published in 2019 and the metric category shows 90%, that means that the article or review is performing better than 90% of the other articles/reviews published in that journal in 2019, 2018 and 2017.
Citation Benchmarking is provided by Scopus and SciVal and is different from the metrics context provided by PlumX Metrics.
Metrics Details
- Citations17
- Citation Indexes17
- 17
- CrossRef15
- Captures2
- Readers2
Article Description
Amiodarone and its major metabolite, desethylamiodarone, were measured in the plasma, white blood cells (WBCs) and red blood cells (RBCs) of 14 patients receiving chronic amiodarone therapy. The mean plasma concentrations (± standard error of the mean) of amiodarone and desethylamiodarone were 2.4 ± 0.6 and 1.6 ± 0.4 μg/ml, respectively. The drug level in the WBCs was 62 ± 12 μg/g protein during the early loading phase and 106 ± 33 μg/g protein during maintenance phase of amiodarone therapy. Desethylamiodarone concentration in the WBCs was 42 ± 18 and 190 ± 33 μg/g protein during the loading and maintenance phases, respectively. Although a trend in WBC to plasma concentration was seen, there was no linear correlation between these levels. In 1 patient with severe neuropathy, biopsy of the nerve and muscle showed high concentrations of both amiodarone and desethylamiodarone. Although there was a decrease in tissue drug levels, proportionately high tissue:plasma drug levels were detected at the time of necropsy approximately 6.5 months after amiodarone was discontinued in this patient. Neutrophils from all patients receiving chronic amiodarone therapy showed multiple myelin-like polymorphic inclusion bodies (onionoid bodies) upon electron microscopic examination. Our observations suggest that WBC drug concentrations and electron microscopic changes may provide a means of correlating tissue concentrations and of following patients receiving chronic amiodarone therapy.
Bibliographic Details
http://www.sciencedirect.com/science/article/pii/0002914986908568; http://dx.doi.org/10.1016/0002-9149(86)90856-8; http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0022456455&origin=inward; http://www.ncbi.nlm.nih.gov/pubmed/3953455; https://linkinghub.elsevier.com/retrieve/pii/0002914986908568; http://dx.doi.org/10.1016/0002-9149%2886%2990856-8; https://dx.doi.org/10.1016/0002-9149%2886%2990856-8
Elsevier BV
Provide Feedback
Have ideas for a new metric? Would you like to see something else here?Let us know